Depending on the type of cell, that can be pretty often. Many proteins are involved in everyday DNA repair, but if they are mutated, the repair system breaks down and cancer can occur. Cells have two complicated ways to repair these breaks, which can affect the stability of the entire genome.
Roger A. Greenberg, M.D., Ph.D., associate investigator, Abramson Family Cancer Research Institute and associate professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania, together with postdoctoral researcher Jiangbo Tang Ph.D. and colleagues, found a key determinant in the balance between two proteins, BRCA1 and 53BP1, in the DNA repair machinery. Breast and ovarian cancer are associated with a breakdown in the repair systems involving these proteins. Their findings appear in the latest online issue of Nature Structural & Molecular Biology.
The two proteins, BRCA1 and 53BP1, control which of two cell-repair mechanisms will be used: homologous recombination or non-homologous end-joining, technically speaking. This competition has proven to be a key factor in determining whether a cell becomes cancer prone as well as how a cancer cell will respond to chemotherapy.
The key step of the balance is acetylation, the chemical process of adding a compound called an acetyl group to other cellular molecules.
The researchers asked what cell signals determine whether BRCA or 53BP1 predominates at a DNA break site.
DNA in the nucleus is tightly packed around proteins called histones. Acetylation at a specific spot on histone H4 determines the answer. If H4 is acetylated at a specific location, then 53BP1 binding near the broken DNA region is strongly reduced. This leaves BRCA1 free to do the work, kicking in the homologous recombination tool to repair the break.
On the other hand, if acetylation is reduced, 53BP1 outcompetes BRCA1 at a break and the non-homologous end-joining tool repairs the break.
This mechanism can help explain resistance to a promising chemotherapy called PARP inhibition seen in patients and mouse models with BRCA1 mutations. Work from several other research teams surprisingly has shown that if neither BRCA nor 53BP1 are available, then the homologous recombination system goes into action even in the absence of BRCA1 and BRCA1 mutant cancer cells become resistant to PARP inhibitors.
Because of this, Greenberg says, there are some possible applications for making PARP chemotherapy more sensitive: "If you could inhibit specific acetylation events, then a patient's response to PARP inhibitors might be enhanced by hyperactivating 53BP1 binding to breaks in the context of BRCA1 deficient cancers. What's more, measuring the levels of acetylation at H4 might predict how responsive an individual is to PARP inhibitors."
"The story didn't fall into place the way we thought it would," says Greenberg. "We didn't realize that it was a combination of two epigenetic marks that drives the repair system. However, we were able to show that 53BP1 doesn't bind well to regions of histone H4 that are acetylated at a specific location on H4. Collaboration with Georges Mer, a structural biologist at the Mayo Clinic, helped provide the molecular basis for these findings. We think there will be further complexity to this regulation, creating the possibility for the discovery of additional mechanisms that regulate DNA repair pathways and response to therapy and potential new targets for diagnosis and therapy."
Co-authors are Nam Woo Cho, Erica M. Manion, Niraj M. Shanbhag, all from Penn, and Gaofeng Cui, Maria Victoria Botuyan, and Georges Mer, from the Department of Biochemistry and Molecular Biology, Mayo Clinic.
The research was supported by the National Cancer Institute (1R01CA138835-01, 1R01CA132878, P50CA116201), a Research Scholar Grant from the American Cancer Society, a DOD Breast Cancer Idea Award, a UPENN-FCCC SPORE Pilot Grant, and funds from the Abramson Family Cancer Research Institute and Basser Research Center for BRCA.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital — the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
Karen Kreeger | EurekAlert!
How to become a T follicular helper cell
31.07.2015 | La Jolla Institute for Allergy and Immunology
Heating and cooling with light leads to ultrafast DNA diagnostics
31.07.2015 | University of California - Berkeley
Mit ultrakalten Atomen lässt sich ein neuer Materiezustand beobachten, in dem das System nicht ins thermische Gleichgewicht kommt.
Was passiert, wenn man kaltes und heißes Wasser mischt? Nach einer Weile ist das Wasser lauwarm – das System hat ein neues thermisches Gleichgewicht erreicht....
Using ultracold atoms trapped in light crystals, scientists from the MPQ, LMU, and the Weizmann Institute observe a novel state of matter that never thermalizes.
What happens if one mixes cold and hot water? After some initial dynamics, one is left with lukewarm water—the system has thermalized to a new thermal...
Physikern der Universitäten Regensburg und Marburg ist es gelungen, die von einem starken Lichtfeld getriebene Bewegung von Elektronen in einem Halbleiter in extremer Zeitlupe zu beobachten. Dabei konnten sie ein grundlegend neues Quantenphänomen entschlüsseln. Die Ergebnisse der Wissenschaftler sind jetzt in der renommierten Fachzeitschrift „Nature“ veröffentlicht worden (DOI: 10.1038/nature14652).
Die rasante Entwicklung in der Elektronik mit Taktraten bis in den Gigahertz-Bereich hat unser Alltagsleben revolutioniert. Sie stellt jedoch auch Forscher...
Physicists from Regensburg and Marburg, Germany have succeeded in taking a slow-motion movie of speeding electrons in a solid driven by a strong light wave. In the process, they have unraveled a novel quantum phenomenon, which will be reported in the forthcoming edition of Nature.
The advent of ever faster electronics featuring clock rates up to the multiple-gigahertz range has revolutionized our day-to-day life. Researchers and...
Erstmals konnte das chemische Element Lithium in der ausgestoßenen Materie einer Nova nachgewiesen werden. Beobachtungen von Nova Centauri 2013 mit Teleskopen des La Silla-Observatoriums der ESO und in der Nähe von Santiago de Chile helfen bei der Aufklärung des Rätsels, warum so viele junge Sterne mehr von diesem Element enthalten als erwartet. Diese Entdeckung liefert ein seit langem fehlendes Teil im Puzzle der chemischen Entwicklungsgeschichte unserer Galaxie und ist ein großer Fortschritt für das Verständnis des Mischungsverhältnisses der chemischen Elemente in den Sternen unserer Milchstraße.
Das leichte chemische Element Lithium ist eines der wenigen Elemente, das nach unserer Modellvorstellung auch beim Urknall vor 13,8 Milliarden Jahren...
31.07.2015 | Veranstaltungen
30.07.2015 | Veranstaltungen
30.07.2015 | Veranstaltungen
31.07.2015 | Seminare Workshops
31.07.2015 | Seminare Workshops
31.07.2015 | Verkehr Logistik